Publication:
How Have the Clinical, Laboratory, Treatment Features and Outcomes in Children With Lupus Nephritis Progressed Over the Last 30 Years

dc.authorscopusid57201394316
dc.authorscopusid59979277300
dc.authorscopusid59978854200
dc.authorscopusid58484049700
dc.authorscopusid57205142178
dc.authorscopusid59979561300
dc.authorscopusid6603035705
dc.authorwosidNalcacioglu, Hulya/L-1713-2016
dc.authorwosidGezgin Yıldırım, Deniz/Iap-2930-2023
dc.authorwosidKisaoglu, Hakan/Gvt-0229-2022
dc.authorwosidBakkaloglu, Sevcan/Aae-9884-2021
dc.authorwosidGaripçin, Pınar/Hhs-9319-2022
dc.authorwosidKalyoncu, Mukaddes/Aam-2913-2021
dc.contributor.authorYildirim, Deniz Gezgin
dc.contributor.authorKaracayir, Nihal
dc.contributor.authorKisaoglu, Hakan
dc.contributor.authorBulbul, Aydan Yekeduz
dc.contributor.authorGaripcin, Pinar
dc.contributor.authorNalcacioglu, Hulya
dc.contributor.authorBakkaloglu, Sevcan A.
dc.contributor.authorIDGaripcin, Pinar/0000-0001-6713-6410
dc.contributor.authorIDPoyrazoğlu, Muammer Hakan/0000-0002-5142-8432
dc.contributor.authorIDKaraçayır, Nihal/0000-0001-5038-7539
dc.contributor.authorIDKısaoğlu, Hakan/0000-0002-1095-3222
dc.contributor.authorIDYekedüz Bülbül, Aydan/0000-0002-6725-537X
dc.contributor.authorIDNalcacioglu, Hulya/0000-0002-0686-9714
dc.contributor.authorIDBakkaloglu Ezgu, Sevcan Azime/0000-0001-6530-9672
dc.date.accessioned2025-12-11T01:39:39Z
dc.date.issued2025
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Yildirim, Deniz Gezgin; Karacayir, Nihal; Bakkaloglu, Sevcan A.] Gazi Univ, Fac Med, Dept Pediat Rheumatol, TR-06500 Ankara, Turkiye; [Kisaoglu, Hakan; Kalyoncu, Mukaddes] Karadeniz Tech Univ, Fac Med, Dept Pediat Rheumatol, Trabzon, Turkiye; [Bulbul, Aydan Yekeduz; Garipcin, Pinar; Poyrazoglu, Hakan] Erciyes Univ, Fac Med, Dept Pediat Rheumatol, Kayseri, Turkiye; [Nalcacioglu, Hulya] Ondokuz Mayis Univ, Fac Med, Dept Pediat Nephrol, Samsun, Turkiye; [Kalyoncu, Mukaddes] Karadeniz Tech Univ, Fac Med, Dept Pediat Nephrol, Trabzon, Turkiye; [Poyrazoglu, Hakan] Erciyes Univ, Fac Med, Dept Pediat Nephrol, Kayseri, Turkiye; [Bakkaloglu, Sevcan A.] Gazi Univ, Fac Med, Dept Pediat Nephrol, Ankara, Turkiyeen_US
dc.descriptionGaripcin, Pinar/0000-0001-6713-6410; Poyrazoğlu, Muammer Hakan/0000-0002-5142-8432; Karaçayır, Nihal/0000-0001-5038-7539; Kısaoğlu, Hakan/0000-0002-1095-3222; Yekedüz Bülbül, Aydan/0000-0002-6725-537X; Nalcacioglu, Hulya/0000-0002-0686-9714; Kalyoncu, Mukaddes/0000-0001-5378-939X; Bakkaloglu Ezgu, Sevcan Azime/0000-0001-6530-9672en_US
dc.description.abstractObjectives Management of systemic lupus erythematosus (SLE) through new treatment options has improved lupus nephritis (LN) prognosis. The aim of this study was to compare the changes in the demographic, laboratory, and treatment characteristics, prognosis, and outcomes of paediatric-onset LN patients over 30 years. Methods We retrospectively reviewed the medical records of 103 paediatric-onset LN patients. Patients were divided into two subgroups according to the years of LN diagnosis. Group 1 consisted of patients diagnosed with LN between the years of 1993 and 2005, and group 2 consisted of patients diagnosed with LN between the years of 2006 and 2023. Results The mean age at diagnosis of SLE, age at diagnosis of LN, time to LN development, and mean delay time to diagnosis were significantly higher in group 1 (P < 0.001, P < 0.001, P = 0.049, and P = 0.004, respectively). Baseline Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) scores were higher and anti-phospholipid antibody positivity was more frequent in group 1 (P = 0.040 and P = 0.025, respectively). Azathioprine in the maintenance phase was given more frequently in group 1 (P = 0.016), while rituximab was more frequently used in group 2 (P = 0.042). In both groups, the majority of the patients had proliferative LN (class III and/or class IV) (53.5% in group 1 vs. 68% in group 2). Complete renal remission was significantly more common in group 2 (P = 0.005), while end-stage kidney disease (ESKD) and death were significantly more common in group 1 (P = 0.005 and P = 0.001, respectively). Proteinuria and SLEDAI scores at the first visit were independent risk factors for progression to ESKD (P = 0.037 and P = 0.024). Conclusion Over the years, there have been significant improvements in the diagnosis and management of children with SLE resulting in an earlier diagnosis, lower disease activity at onset, and improved outcomes.en_US
dc.description.woscitationindexScience Citation Index Expanded
dc.identifier.doi10.1093/rheumatology/keaf151
dc.identifier.endpage4282en_US
dc.identifier.issn1462-0324
dc.identifier.issn1462-0332
dc.identifier.issue7en_US
dc.identifier.pmid40108363
dc.identifier.scopus2-s2.0-105009951373
dc.identifier.scopusqualityQ1
dc.identifier.startpage4275en_US
dc.identifier.urihttps://doi.org/10.1093/rheumatology/keaf151
dc.identifier.urihttps://hdl.handle.net/20.500.12712/45234
dc.identifier.volume64en_US
dc.identifier.wosWOS:001452957800001
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofRheumatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLupus Nephritisen_US
dc.subjectOutcomeen_US
dc.subjectPediatric Rheumatologyen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.titleHow Have the Clinical, Laboratory, Treatment Features and Outcomes in Children With Lupus Nephritis Progressed Over the Last 30 Yearsen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files